₹5,410
▲ +78.37 +1.47%
As of 21 Sept 2026 · delayed
NSE Listed · Healthcare
Alkem Laboratories Limited (ALKEM)
Volume: 94,96852W Range:₹5,051₹5,933.5
Key Ratios
Checked 2h agoMarket Cap₹63,728 Cr
Current Price₹5,410
Previous Close₹5,331.63
High / Low (52w)₹5,933.5 / ₹5,051
Volume94,968
Avg Vol (1W)—
Avg Vol (1M)—
Stock P/E29.57
Book Value₹1,155.87
Dividend Yield37%
ROE16.66%
ROA10.57%
Revenue (TTM)—
Revenue Growth—
Profit Margin—
Total Debt₹311 Cr
Shares Outstanding12 Cr
Face Value₹2
EPS (TTM)₹180.23
P/B4.61
Debt / Equity14.27
50 DMA₹5,443.73
200 DMA₹5,492.7
Day change+1.47%
Price Chart
₹5,410▼ 1.46% · 1Y
2025-09-232026-09-21
20-day avg volume: 1.4L shares
Pros
- Healthy return on equity of 16.7%.
- Pays a dividend yield of 37.0%.
- Company is almost debt-free.
- Revenue grew 13% YoY.
Quarterly Results
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3,415 Cr | ₹3,374 Cr | ₹3,144 Cr | ₹3,371 Cr | ₹4,001 Cr | ₹3,737 Cr | ₹3,603 Cr | ₹3,740 Cr |
| EBITDA | ₹808 Cr | ₹767 Cr | ₹425 Cr | ₹788 Cr | ₹931 Cr | ₹876 Cr | ₹612 Cr | ₹819 Cr |
| Net Profit | ₹689 Cr | ₹626 Cr | ₹306 Cr | ₹664 Cr | ₹765 Cr | ₹636 Cr | ₹236 Cr | ₹520 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹13,458 Cr | ₹2,045 Cr | ₹2,372 Cr | ₹2,542 Cr | ₹2,491 Cr | ₹2,258 Cr | ₹15,296 Cr | ₹2,668 Cr |
| EBITDA | ₹2,649 Cr | ₹317 Cr | ₹678 Cr | ₹813 Cr | ₹760 Cr | ₹472 Cr | ₹3,207 Cr | ₹816 Cr |
| Net Profit | ₹2,165 Cr | ₹277 Cr | ₹656 Cr | ₹787 Cr | ₹622 Cr | ₹217 Cr | ₹2,302 Cr | ₹570 Cr |
| EPS | 181.11 | — | — | — | — | — | 192.51 | — |
Balance Sheet
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹8,208 Cr | ₹9,946 Cr | ₹11,519 Cr | ₹14,069 Cr | ₹13,757 Cr | ₹15,575 Cr | ₹17,691 Cr | ₹20,873 Cr |
| Total Liabilities | ₹2,636 Cr | ₹3,637 Cr | ₹3,961 Cr | ₹5,222 Cr | ₹4,322 Cr | ₹4,861 Cr | ₹5,257 Cr | ₹6,524 Cr |
| Equity | ₹5,572 Cr | ₹6,309 Cr | ₹7,558 Cr | ₹8,847 Cr | ₹9,435 Cr | ₹10,714 Cr | ₹12,434 Cr | ₹14,349 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹1,029 Cr | ₹868 Cr | ₹1,666 Cr | ₹1,508 Cr | ₹1,956 Cr | ₹2,355 Cr | ₹2,417 Cr | ₹2,592 Cr |
| Investing | ₹-314 Cr | ₹-741 Cr | ₹-999 Cr | ₹-1,435 Cr | ₹113 Cr | ₹-1,008 Cr | ₹-1,299 Cr | ₹-1,667 Cr |
| Financing | ₹-379 Cr | ₹79 Cr | ₹-272 Cr | ₹380 Cr | ₹-1,761 Cr | ₹-1,145 Cr | ₹-811 Cr | ₹-503 Cr |
| Free Cash Flow | ₹1,029 Cr | ₹868 Cr | ₹1,666 Cr | ₹1,508 Cr | ₹1,956 Cr | ₹2,355 Cr | ₹2,417 Cr | ₹2,592 Cr |
Shareholding
Promoter 62.44% Institutions 27.79% Public 9.76%
About Alkem Laboratories Limited
Healthcare · Drug Manufacturers - Specialty & Generic
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology, central nervous system, anti-diabetic, iron deficiency, pain management, and urology, as well as vitamins, minerals, and nutrients. It also provides cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. Alkem Laboratories Limited was incorporated in 1973 and is based in Mumbai, India.
www.alkemlabs.com ↗Efficiency & Working Capital
ROCE18.6%
Interest Coverage18.9
Dividend Payout—
Debtor Days74 d
Inventory Days83 d
Payable Days56 d
Cash Conversion Cycle101 d
Working Capital Days157 d
Shareholding Details
As of 2026-06-30
Promoter49.7%
FII10.4%
DII22.6%
Institutions33%
Public17.3%
Promoter Pledge0%
No. of Shareholders62,822
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 56.7% | 56.7% | 56.7% | 56.4% | 55.7% | 55.7% | 55.1% | 53% | 51.2% | 51.2% | 51.2% | 49.7% |
| FIIs | 6% | 8.5% | 9.1% | 8.7% | 9% | 10.1% | 9.4% | 9.1% | 9.5% | 10% | 10.2% | 10.4% |
| DIIs | 17.6% | 14.9% | 15.6% | 18.6% | 19.2% | 18% | 19.4% | 21.8% | 21.9% | 21.5% | 21.4% | 22.6% |
| Public | 19.6% | 19.8% | 18.5% | 16.4% | 16.1% | 16.2% | 16% | 16.1% | 17.4% | 17.3% | 17.2% | 17.3% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 69,442 | 65,184 | 65,830 | 69,627 | 74,744 | 84,038 | 84,326 | 79,740 | 67,196 | 64,536 | 62,835 | 62,822 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202603 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Sarandhar Singh * (please Refer Notes) | Shareholding of Promoter and Promoter Group | 18.3% | 2.19 Cr |
| Basudeo Narain Singh | Shareholding of Promoter and Promoter Group | 7.3% | 86,95,360 |
| Mritunjay Kumar Singh | Shareholding of Promoter and Promoter Group | 6.4% | 76,82,000 |
| Madhurima Singh& (please Refer Notes) | Shareholding of Promoter and Promoter Group | 6.2% | 73,93,939 |
| Hdfc Mutual Fund - Hdfc Mid-cap Fund | Public Shareholding | 4.8% | 57,06,750 |
| Icici Prudential Multi-asset Fund | Public Shareholding | 3.6% | 42,68,472 |
| Madhurima Singh@ (please Refer Notes) | Shareholding of Promoter and Promoter Group | 2.6% | 30,92,875 |
| Kishor Kumar Singh | Public Shareholding | 2.5% | 29,73,312 |
| Alok Kumar | Public Shareholding | 2.3% | 27,64,719 |
| Ashok Kumar | Public Shareholding | 2.3% | 26,88,000 |
| Seema Singh | Shareholding of Promoter and Promoter Group | 2.2% | 25,79,045 |
| Deepak Kumar Singh | Public Shareholding | 2% | 24,02,140 |
| Archana Singh | Shareholding of Promoter and Promoter Group | 2% | 23,94,050 |
| Sbi Large & Midcap Fund | Public Shareholding | 2% | 23,83,162 |
| Nippon Life India Trustee Ltd- A/c Nippon India Growth Mid Cap Fund | Public Shareholding | 1.9% | 22,34,434 |
| Dsp Midcap Fund | Public Shareholding | 1.8% | 21,32,118 |
| Nps Trust- A/c Hdfc Pension Fund Management Limited Scheme E - Tier I | Public Shareholding | 1.5% | 17,41,075 |
| Life Insurance Corporation Of India - P & Gs Fund | Public Shareholding | 1.4% | 17,15,063 |
| Rajesh Kumar | Public Shareholding | 1.4% | 16,84,535 |
| Hdfc Life Insurance Company Limited | Public Shareholding | 1.3% | 15,60,875 |
| Rajeev Ranjan | Public Shareholding | 1.2% | 14,85,342 |
| Aniruddha Singh& (please Refer Notes) | Shareholding of Promoter and Promoter Group | 1% | 12,08,971 |
| Divya Singh& (please Refer Notes) | Shareholding of Promoter and Promoter Group | 1% | 12,08,971 |
| Meghna Singh | Shareholding of Promoter and Promoter Group | 1% | 12,08,650 |
| Shrey Shree Anant Singh | Shareholding of Promoter and Promoter Group | 1% | 11,95,650 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Basudeo N Singh | Chairman/ED & CEO | 2026 |
| SANDEEP SINGH | ED / MD / Promoter | 2026 |
| Mritunjay Kumar Singh | Executive Director | 2026 |
| Madhurima Singh | Executive Director | 2026 |
| SARVESH SINGH | Executive Director | 2026 |
| Srinivas Singh | Executive Director | 2026 |
| Narendra Aneja | Independent Non Exe. Director | 2026 |
| Sujjain Talwar | Independent Non Exe. Director | 2026 |
| Rajeev Kher | Independent Non Exe. Director | 2026 |
| R L Shenoy | Independent Non Exe. Director | 2026 |
| Neela Bhattacherjee | Independent Non Exe. Director | 2026 |
| Diwakar Gupta | Independent Non Exe. Director | 2026 |
| Manish Narang | President / Company Secretary / Compliance Officer | 2026 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Pharma Business | ₹2,708 Cr | 100% |
| Others (Investing & Real Estate) | ₹0 Cr | 0% |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| India | ₹7,023 Cr | 72.7% |
| USA | ₹1,617 Cr | 16.7% |
| Other Countries | ₹1,024 Cr | 10.6% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2026 | ₹2 | 50 | 24 | 24 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-08-14 | Board Meetings | — |
| forthcoming | 2026-08-07 | Dividend (10/- per share) | Final |
| dividend | 2026-08-07 | ₹10 (500%) | Final |
| dividend | 2026-02-20 | ₹43 (2150%) | Interim |
| dividend | 2025-08-08 | ₹8 (400%) | Final |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2026 | 7,948 | 172 | 0 | 205 | 0 | 8,408 |
| 2026 | 1,916 | 4 | 0 | 0 | 0 | 1,920 |
| 2026 | 1,825 | 168 | 0 | 194 | 0 | 2,268 |
Insider / Designated-Person Trades
17 recent disclosure(s)
Mr. Deepak Kumar SinghDisposal · 25,000
Mritunjay Kumar SinghAcquisition · 1,643
Mritunjay Kumar SinghAcquisition · 3,357
Dhananjay and Madhurima Singh TrustAcquisition · 1,050
Dhananjay and Madhurima Singh TrustAcquisition · 2,000
Mr. Deepak Kumar SinghDisposal · 2,000
Substantial Acquisitions (SAST)
1 disclosure(s)
Market24/08/2026 · 25,019
Company Information
Incorporated1973
ChairmanBasudeo N Singh
AuditorDeloitte Haskins & Sells LLP
Investor Email[email protected] ; [email protected]
📍 Alkem House SenapatiBapat Marg, Lower Parel, Mumbai, Maharashtra, 400013
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search